Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
IN0V8
IN0V8 Jul. 16 at 2:46 PM
$EYPT Opportunity Stifel initiates coverage with buy rating; target price $40
1 · Reply
rizzato
rizzato Jul. 16 at 2:39 PM
$EYPT https://www.benzinga.com/analyst-stock-ratings/initiation/26/07/60492495/this-rambus-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday?mod=mw_quote_news
0 · Reply
rizzato
rizzato Jul. 16 at 2:38 PM
$EYPT https://www.gurufocus.com/news/8961947/eypt-initiated-coverage-by-stifel-buy-rating-with-40-price-target
0 · Reply
Quantumup
Quantumup Jul. 16 at 10:54 AM
Stifel🏁 $EYPT and said -- We initiate coverage of EyePoint (EYPT) with a Buy rating, $40 TP. $OCUL $SRZN FDMT REGN RHHBY KOD Here's what Stifel went on to say in its initiation report: https://x.com/Quantumup1/status/2077708075130142843?s=20
1 · Reply
npcpaperboy
npcpaperboy Jul. 16 at 8:25 AM
$EYPT news today needs some vol target price $40
0 · Reply
npcpaperboy
npcpaperboy Jul. 16 at 8:21 AM
$EYPT has news today
0 · Reply
sboks
sboks Jul. 15 at 6:53 PM
0 · Reply
Poet5
Poet5 Jul. 15 at 5:07 PM
$EYPT Let this sink back to 10.00. There and below will be a SCREAMING buy!
0 · Reply
Bernic88
Bernic88 Jul. 15 at 1:39 PM
$EYPT Not good at all right now
0 · Reply
rizzato
rizzato Jul. 14 at 8:04 PM
0 · Reply
Latest News on EYPT
EyePoint initiated with a Buy at Stifel

2026-07-15T20:15:13.000Z - 21 hours ago

EyePoint initiated with a Buy at Stifel


EyePoint Appoints Tarek S. Hassan, M.D.

Jul 13, 2026, 7:00 AM EDT - 3 days ago

EyePoint Appoints Tarek S. Hassan, M.D.


EyePoint assumed with an Overweight at Cantor Fitzgerald

2026-07-08T11:50:27.000Z - 8 days ago

EyePoint assumed with an Overweight at Cantor Fitzgerald


EyePoint price target raised to $65 from $29 at Chardan

2026-07-01T10:16:22.000Z - 15 days ago

EyePoint price target raised to $65 from $29 at Chardan


EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 9:00 AM EDT - 7 weeks ago

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum


EyePoint reports Q1 EPS (99c), consensus (81c)

2026-05-07T07:35:29.000Z - 2 months ago

EyePoint reports Q1 EPS (99c), consensus (81c)


EyePoint Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

EyePoint Earnings Call Transcript: Q1 2026


EyePoint Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

EyePoint Earnings release: Q1 2026


EyePoint Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

EyePoint Quarterly report: Q1 2026


EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

EyePoint Proxy statement: Proxy filing


EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

EyePoint Proxy statement: Proxy filing


EyePoint Slides: Corporate presentation

Apr 23, 2026, 7:00 AM EDT - 3 months ago

EyePoint Slides: Corporate presentation


EyePoint price target raised to $35 from $31 at Citi

2026-03-09T10:55:47.000Z - 4 months ago

EyePoint price target raised to $35 from $31 at Citi


EyePoint price target raised to $30 from $23 at H.C. Wainwright

2026-03-05T11:11:09.000Z - 4 months ago

EyePoint price target raised to $30 from $23 at H.C. Wainwright


EyePoint price target raised to $29 from $27 at Chardan

2026-03-04T19:55:31.000Z - 4 months ago

EyePoint price target raised to $29 from $27 at Chardan


EyePoint Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

EyePoint Earnings Call Transcript: Q4 2025


EyePoint Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

EyePoint Annual report: Q4 2025


EyePoint Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

EyePoint Earnings release: Q4 2025


EyePoint reports Q4 EPS (81c), consensus (75c)

2026-03-04T12:10:17.000Z - 4 months ago

EyePoint reports Q4 EPS (81c), consensus (75c)


EyePoint expects cash to fund operations into Q4 2027

2026-03-04T12:09:56.000Z - 4 months ago

EyePoint expects cash to fund operations into Q4 2027


EyePoint Slides: Investor presentation

Mar 2, 2026, 7:00 AM EST - 4 months ago

EyePoint Slides: Investor presentation


EyePoint price target raised to $36 from $33 at Mizuho

2026-02-19T12:28:49.000Z - 5 months ago

EyePoint price target raised to $36 from $33 at Mizuho


EyePoint appoints Campbell as Chief Commercial Officer

2026-02-18T12:05:24.000Z - 5 months ago

EyePoint appoints Campbell as Chief Commercial Officer


EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 5 months ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer


EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 6 months ago

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference


EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 6 months ago

EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference


EyePoint Slides: Investor presentation

Jan 12, 2026, 7:00 AM EST - 6 months ago

EyePoint Slides: Investor presentation


EyePoint Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 8 months ago

EyePoint Transcript: Stifel 2025 Healthcare Conference


EyePoint Slides: FY 2025

Nov 12, 2025, 10:40 AM EST - 8 months ago

EyePoint Slides: FY 2025


EyePoint Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

EyePoint Earnings Call Transcript: Q3 2025


EyePoint Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

EyePoint Quarterly report: Q3 2025


EyePoint Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

EyePoint Earnings release: Q3 2025


EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 9 months ago

EyePoint Announces Pricing of Public Offering


EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 9 months ago

EyePoint Announces Proposed Public Offering of Common Stock


EyePoint Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:45 PM EDT - 11 months ago

EyePoint Transcript: Cantor Global Healthcare Conference 2025


EyePoint Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 2:30 PM EDT - 11 months ago

EyePoint Transcript: Citi's Biopharma Back to School Conference


EyePoint Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q2 2025


EyePoint Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q2 2025


EyePoint Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q2 2025


EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 8:30 AM EDT - 1 year ago

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum


EyePoint Slides: Investor Presentation

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Slides: Investor Presentation


EyePoint Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q1 2025


EyePoint Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q1 2025


EyePoint Earnings release: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q1 2025


EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings Call Transcript: Q4 2024


EyePoint Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Annual report: Q4 2024


EyePoint Earnings release: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings release: Q4 2024


EyePoint Slides: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

EyePoint Slides: TD Cowen 45th Annual Healthcare Conference


EyePoint Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

EyePoint Transcript: Guggenheim SMID Cap Biotech Conference


EyePoint Transcript: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Transcript: Status Update


EyePoint Press release: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Press release: Status Update


EyePoint Slides: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Slides: Status Update


EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference


EyePoint Slides: FY 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

EyePoint Slides: FY 2025


EyePoint Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 4:15 PM EST - 1 year ago

EyePoint Transcript: UBS Global Healthcare Conference 2024


EyePoint Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Quarterly report: Q3 2024


EyePoint Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Earnings release: Q3 2024


EyePoint Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 2:30 PM EDT - 1 year ago

EyePoint Transcript: UBS Virtual Ophthalmology Day


EyePoint Registration statement: Registration Filing

Aug 8, 2024, 8:00 AM EDT - 2 years ago

EyePoint Registration statement: Registration Filing


EyePoint Quarterly report: Q2 2024

Aug 7, 2024, 7:15 AM EDT - 2 years ago

EyePoint Quarterly report: Q2 2024


EyePoint Earnings release: Q2 2024

Aug 7, 2024, 7:15 AM EDT - 2 years ago

EyePoint Earnings release: Q2 2024


EyePoint Slides: Investor Presentation

Jul 9, 2024, 6:00 AM EDT - 2 years ago

EyePoint Slides: Investor Presentation


EyePoint Transcript: R&D Day 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: R&D Day 2024


EyePoint Press release: FY 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Press release: FY 2024


EyePoint Slides: FY 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Slides: FY 2024


EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024


EyePoint Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Quarterly report: Q1 2024


EyePoint Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Earnings release: Q1 2024


IN0V8
IN0V8 Jul. 16 at 2:46 PM
$EYPT Opportunity Stifel initiates coverage with buy rating; target price $40
1 · Reply
rizzato
rizzato Jul. 16 at 2:39 PM
$EYPT https://www.benzinga.com/analyst-stock-ratings/initiation/26/07/60492495/this-rambus-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday?mod=mw_quote_news
0 · Reply
rizzato
rizzato Jul. 16 at 2:38 PM
$EYPT https://www.gurufocus.com/news/8961947/eypt-initiated-coverage-by-stifel-buy-rating-with-40-price-target
0 · Reply
Quantumup
Quantumup Jul. 16 at 10:54 AM
Stifel🏁 $EYPT and said -- We initiate coverage of EyePoint (EYPT) with a Buy rating, $40 TP. $OCUL $SRZN FDMT REGN RHHBY KOD Here's what Stifel went on to say in its initiation report: https://x.com/Quantumup1/status/2077708075130142843?s=20
1 · Reply
npcpaperboy
npcpaperboy Jul. 16 at 8:25 AM
$EYPT news today needs some vol target price $40
0 · Reply
npcpaperboy
npcpaperboy Jul. 16 at 8:21 AM
$EYPT has news today
0 · Reply
sboks
sboks Jul. 15 at 6:53 PM
0 · Reply
Poet5
Poet5 Jul. 15 at 5:07 PM
$EYPT Let this sink back to 10.00. There and below will be a SCREAMING buy!
0 · Reply
Bernic88
Bernic88 Jul. 15 at 1:39 PM
$EYPT Not good at all right now
0 · Reply
rizzato
rizzato Jul. 14 at 8:04 PM
0 · Reply
KimboIce
KimboIce Jul. 13 at 9:24 PM
$EYPT I’m guessing last patient in Lugano will be seen this week. Database will be unlocked next week ?
4 · Reply
laaarsas
laaarsas Jul. 13 at 5:36 PM
$EYPT How strong were ph2 DAVIO results do you think? How strong do you think the inference to ph3 is?
0 · Reply
rizzato
rizzato Jul. 13 at 1:01 PM
$EYPT Back to feed EyePoint appoints renowned retina specialist Dr Tarek Hassan as chief strategic science officer ● 2 hours ago EyePoint has appointed Tarek S. Hassan, M.D., as Senior Vice President and Chief Strategic Science Officer. Dr Hassan, a globally recognised retina specialist with over 35 years of experience, will provide strategic guidance across the company's portfolio, including its lead programme, DURAVYU (vorolanib intravitreal insert). The appointment comes as EyePoint expects topline data from Phase 3 wet age-related macular degeneration trials for DURAVYU in the near future. Dr Hassan will report to President and CEO Jay S. Duker, M.D., and serve on the executive leadership team. Dr Hassan is currently Professor of Ophthalmology at Oakland University William Beaumont School of Medicine and a Senior Partner at Associated Retinal Consultants. He has participated in over 180 multicentre clinical trials and authored more than 250 peer-reviewed publications.
0 · Reply
rizzato
rizzato Jul. 13 at 5:17 AM
$EYPT https://www.benzinga.com/markets/options/26/07/60395455/6-health-care-stocks-whale-alerts-today-s-session?mod=mw_quote_news
0 · Reply
rizzato
rizzato Jul. 13 at 5:16 AM
$EYPT For EYPT (NASDAQ:EYPT), we notice a call option sweep that happens to be bullish, expiring in 98 day(s) on October 16, 2026. This event was a transfer of 85 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $320.0 per contract. There were 475 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold.
0 · Reply
Jmoney55555
Jmoney55555 Jul. 12 at 7:51 AM
$EYPT this company deserves more attention.
2 · Reply
Kashking03
Kashking03 Jul. 10 at 1:39 PM
$EYPT rug pull?
1 · Reply
hellomynameiz
hellomynameiz Jul. 10 at 12:12 PM
0 · Reply
rizzato
rizzato Jul. 9 at 9:04 PM
1 · Reply
Bernic88
Bernic88 Jul. 9 at 8:11 PM
$EYPT Definitely very interesting; I’ve opened a position with 1,000 shares. Good luck to everyone here🍀
0 · Reply
rizzato
rizzato Jul. 7 at 9:59 PM
$EYPT again
1 · Reply
Poet5
Poet5 Jul. 6 at 10:12 PM
$EYPT Beautiful upward consolidation, solid continuous buying today and Now through early to mid August (first trial phase III Lugano results) September/October (2nd trial III Lugano results), DME full enrollment, Oct/Nov. 45-60.00.
0 · Reply